45例晚期非小细胞肺癌EGFR-TKIs治疗获益后出现孤立进展后联合局部治疗的回顾性分析

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are routine treatments for non-small cell lung cancer (NSCLC) with EGFR mutation. Different clinical modes can be used to treat patients with TKI resistance, one of which is solitary progression. The aim of this study is to analyze available treatments for patients undergoing solitary progression. METHODS: Clinical data of 45 patients with advanced NSCLC who received local radiotherapy combined with EGFR-TKI after solitary progression were reviewed and analyzed. RESULTS: Among the 45 patients, 11 showed partial response, 23 achieved stable disease state, and 11 experienced progressive disease. The median of progression-free survival (PFS) was 5.9 months. CONCLUSION: Local therapies combined with EGFR-TKIs can prolong the PFS of patients with NSCLC who exhibited solitary progression during EGFR-TKI treatment.